Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574264 | 0.92 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL16626907 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL1066335 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL13715829 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL3854916 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL16606317 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL30596278 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL15943374 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL14262997 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL138261 | 0.79 | SMN1; SMN2 (0.83) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo (NO) | 2019-03-12 | — | — | US | disclosed |
| EP-3052135-B1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIV OSLO (NO) | 2018-07-18 | — | — | EP | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| WO-2015049546-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIVERSITETET I OSLO (NO) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | SMN1; SMN2 3740/4885MAPT 3945/4885LIN28A 1445/4885 |
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | SLC30A6, DDO, SLC30A7 | SMN1; SMN2 3740/4885MAPT 3945/4885LIN28A 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.